May 9, 2024 09:12 AM EDTUpdated 10:45 AM
Financing
Startups

In­fec­tious dis­ease biotech Blue­jay rais­es $182M for he­pati­tis tri­als

Kyle LaHucik

Senior Reporter

Cal­i­for­nia biotech Blue­jay Ther­a­peu­tics has se­cured a megaround to con­tin­ue de­vel­op­ing its treat­ment can­di­dates for chron­ic he­pati­tis D and B.

The $182 mil­lion Se­ries C …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times